Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From HEC Pharm
Victory Swings Back To Gilenya Generics With Latest US Supreme Court Order
Novartis, which reportedly generates $3.8m per day in US Gilenya sales, is once again facing up to the prospect of imminent generic competition to its blockbuster treatment for relapsing-remitting multiple sclerosis, following the latest order by the US Supreme Court.
US Federal Circuit Will Not Stand In Way Of Gilenya Generics
ANDA sponsors targeting Novartis’s Gilenya have been informed by the US Court of Appeals for the Federal Circuit that at an ‘at-risk’ launch is possible, after the originator’s latest petition to the court was denied as it seeks a ruling from the US Supreme Court.
Gilenya Generics May Be Imminent Amid US Federal Circuit Snub
Are US Gilenya generics set to flood the US market? HEC Pharm is hoping so, following a favorable Federal Circuit denial. However, in a bid to maintain its monopoly and avoid a potential $300m hit to its top line, Novartis is taking its fight to the US Supreme Court.
HEC Pharm Awaits Fate As Novartis Petitions On US Gilenya Victory
Novartis is sticking to its plan to continue fighting HEC Pharm in court, after it recently lost a key decision for its Gilenya (fingolimod) blockbuster treatment for multiple sclerosis.
- Generic Drugs
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
- HEC Pharm Co. Ltd.
- Yichang Changjiang Pharmaceutical Co., Ltd.
- Sunshine Lake Pharma Co., Ltd.
- Ruyuan HEC Pharm Co
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.